Oncology Innovation

TAMPA – October 29, 2026 -- Akari Therapeutics (Nasdaq: AKTX) will present its PH1 antibody drug conjugate (ADC) payload at five oncology, ADC and investor conferences in the United States and China during September 2026, as it looks for pharma partners and investors ahead of a planned first-in-human trial by mid-2027.

CEO Abizer Gaslightwala will deliver a keynote and featured presentations. The company says it will discuss global R&D collaboration, platform partnerships and pipeline expansion.

Akari fills a September calendar across Boston, Shanghai, WuXi and New York

The schedule runs from September 9 to September 29:

TAMPA – October 29, 2026 -- Akari Therapeutics (Nasdaq: AKTX) has filed international patent application PCT/US2026/45955, adding claims on how its PH1 payload modulates alternative splicing across multiple cancer-driving genes.

The filing expands the company's intellectual property around PH1, a splicing-modulating payload derived from its proprietary Thailanstatin platform, and around PH1-based antibody drug conjugates (ADCs). Akari contrasts PH1 with conventional ADC payloads that rely on tubulin inhibition, such as vedotin, or DNA damage, such as topoisomerase I inhibitors.

Application claims PH1 shifts VEGF-A splicing to block tumor blood supply

The claims cover PH1 altering VEGF-A splicing in cancer cells. The shift moves from a pro-angiogenic isoform to the anti-angiogenic VEGF-165b isoform, which prevents blood vessel recruitment to tumors.

Raritan, N.J. – September 25, 2026 -- Half of patients with early-line relapsed or refractory multiple myeloma treated with a single infusion of Johnson & Johnson's CARVYKTI® (ciltacabtagene autoleucel) remained alive and progression-free for at least five years without maintenance therapy, according to new long-term data from the Phase 2 CARTITUDE-2 study.

Half of patients reach five-year progression-free survival without maintenance

In the initial subgroup of cohort A (N=20), 10 of 20 patients treated with a single CARVYKTI® infusion remained progression-free at a median follow-up of 60.7 months. Median progression-free survival reached 60.5 months, and the results were presented at the International Myeloma Society Annual Meeting (Abstract #PA-288). Cohort A enrolled patients who had received one to three prior lines of therapy, were exposed to a proteasome inhibitor, and were refractory to lenalidomide.

Suzhou – September 22, 2026 -- Boomray Pharmaceuticals Co., Ltd. has signed an exclusive global license agreement with Novartis Pharma AG for an undisclosed preclinical radioligand therapy (RLT) asset, with total deal value reaching up to USD 900 million.

Novartis secures rights to undisclosed preclinical oncology asset

Under the agreement, BoomRay will be eligible to receive an upfront payment plus development, regulatory, and sales milestone payments totaling up to USD 900 million. The Suzhou-based company will also earn royalties on future global net sales of the licensed program.

Shanghai and Hong Kong – September 17, 2026 -- Antengene Corporation Limited (SEHK: 6996.HK) has published preclinical data showing that combining its CD73 inhibitor ATG-037 with selinexor suppressed tumor growth by 62% in a multiple myeloma mouse model, versus 31% for ATG-037 alone and 43% for selinexor alone. The peer-reviewed paper, developed with the Department of Hematology at Peking University Third Hospital, appears in Cancer Gene Therapy, an SCI journal under Springer Nature (DOI: 10.1038/s41417-026-01078-9).

Seoul – September 17, 2026 -- Johnson & Johnson reported that its RYBREVANT (amivantamab-vmjw) plus chemotherapy combination extended median overall survival to 34.3 months in patients with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer, compared with 27.9 months for chemotherapy alone, according to final data from the Phase 3 PAPILLON study.

Combination therapy nearly doubles historical survival benchmarks

The result marks the longest reported median overall survival for this patient population, which has historically faced a five-year survival rate of just 8 percent and a median overall survival ranging from 16 to 24 months. EGFR exon 20 insertion mutations account for approximately 12 percent of all EGFR mutations and have proven difficult to treat with existing targeted therapies.